Journal of Infection and Public Health
Volume 2, Issue 1 , Pages 47-51 , 2009

Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001–2006)

Received 12 September 2008 ,Revised 4 December 2008 ,Accepted 7 January 2009.

References 

  1. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Aqualitative study of injecting drug user's in Tehran, Iran. Harm Reduct J. 2006;18(3):12
  2. Thomas DL, Ray SC, Lemon SM. In:  Mandell GL,  Bennett JE,  Dolin R editor. Principle and practice of infectious diseases. 6th ed.. USA, Philadelphia: Churchill Livingstone; 2005;p. 1950–1981
  3. Prevention Department of Welfare Organization. A summary report of drug related infectious disease in Iran; 2000.
  4. Asadi S, Marjani M. Prevalence of intravenous drug use-associated infections. Iran J Clin Infect Dis. 2006;1(2):59–62
  5. Carmo RA, Oliveira GC, Guimaraes MD, Oliveira MS, Lima AA, Buzek SC, et al. Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study. Braz J Med Biol Res. 2002;35:589–598
  6. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362
  7. Wharfe G, Smikle M, Dowe G, Buchner L, Choo-Kang E, Graham S, et al. Seroprevalence of hepatitis C virus in haemophiliacs in Jamaica. Hum Antibodies. 2002;11:61–64
  8. Alavian SM. Control of hepatitis C in Iran: vision and missions. Hepatitis Mon. 2007;7(2):57–58
  9. Alavi SM, Etemadi A. HIV/HBV, HIV/HCV AND HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pak J Med Sci. 2007;24(2):358–360
  10. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001;127:475–484
  11. Zali MR, Aghazadeh R, Nowroozi A. Anti-HCV antibody among Iranian IV drug users: is it a serious problem?. Arch Iran Med. 2001;4:115–119
  12. Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan, Iran. World J Gastroenterol. 2005;11:4085–4089
  13. Hernandez-Aguado I, Ramos-Rincon JM, Aviñio MJ, Gonzalez-Aracil J, Pérez-Hoyos S, de la Hera MG, et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17(6):539–544
  14. Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat. 2005 Nov;12(6):655–662
  15. Orton SL, Stramer SL, Dodd RY, Alter MJ. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion. 2004 Feb;44(2):275–281
  16. Moses S, Mestery K, Kaita KD, Minuk GY. Viral hepatitis in a Canadian street-involved population. Am J Public Health. 2002;93(2):123–128
  17. Caiaffa WT, Mingoti SA, Proietti FA, Carneiro-Proietti AB, Silva RC, Lopes AC, et al. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project. J Urban Health. 2003;80(March(1)):106–114
  18. Jahani MR, AlavianSM , Shirzad H, Kabir A, Hajarizadeh B. Distribution of risk factors HBV, HCV and HIV infection in female population with illegal social behavior. Sex Transm infect. 2005;81:185–188
  19. Merino CE, Orozco JA, Rojo MA, Tour A. Prevalence of hepatitis C virus among candida for blood donation at the general hospital in the Mexico. In Vivo. 1994;8:621–623
  20. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002, 1;186(11):1558–64.
  21. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997;26(6):1359–1366
  22. Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F. HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counseling on the compliance of proposed tests. Epidemiol Prev. 2004;28(3):163–168

PII: S1876-0341(09)00002-1

doi: 10.1016/j.jiph.2009.01.001

Journal of Infection and Public Health
Volume 2, Issue 1 , Pages 47-51 , 2009

Article Tools